The suitability of SOCE as new drug target in IBD patients is further supported by the fact that SOCE was reported to be increased in intestinal lymphocytes of IBD patients (Schwarz et al, 2004), which is confirmed by our own observations in this study (Appendix Fig S11), and the increased expression of STIM1 in CD45+ LPMCs in inflamed intestinal tissues of IBD patients (Liang et al, 2022). This evidence concerns the gene PTPRC and inflammatory bowel disease.